Celon Pharma SA CELON PHARMA ORD SHS
Celon Pharma SA CELON PHARMA ORD .../ PLCLNPH00015 /
0RKX
|
- -
|
Chg.
-
|
Volume |
Bid06:00:09 |
Ask06:00:09 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
-PLN
|
-
|
-
Turnover: - |
-Bid Size: - |
-Ask Size: - |
1.38 bill.PLN |
- |
- |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
-0.55 PLN |
-28.57% |
| EPS Diluted: |
- PLN |
-28.57% |
| Revenues per Share: |
4.24 PLN |
11.25% |
| Book Value per Share: |
8.73 PLN |
-7.15% |
| Cash Flow per Share: |
-0.16 PLN |
76.78% |
| Dividend per Share: |
- PLN |
- |
| Total |
in th. |
|
| Revenues: |
216,566.00 PLN |
11.29% |
| Net Income: |
-28,124.00 PLN |
-28.40% |
| Operating Cash Flow: |
-8,314.00 PLN |
- |
| Cash and Cash Equivalents: |
32,359.00 PLN |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
- |
- |
| P/S Ratio: |
6.37 |
3.64 |
| P/BV ratio: |
3.09 |
1.77 |
| P/CF Ratio: |
-165.81 |
-94.94 |
| PEG: |
1.72 |
- |
| Earnings Yield: |
-2.04% |
-3.56% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
1.38 bill. PLN |
789.33 mill. PLN |
| Free Float Market Cap.: |
- PLN |
- PLN |
| Market Cap. / Employee: |
2.68 mill. PLN |
1.53 mill. PLN |
| Shares Outstanding: |
51.06 mill. |
|
Profitability
| Gross Profit Margin: |
- |
| EBIT Margin: |
-12.58% |
| Net Profit Margin: |
-12.99% |
| Return on Equity: |
-6.31% |
| Return on Assets: |
-4.94% |
Financial Strength
| Liquidity I / Cash Ratio: |
37.48% |
| Liquidity II / Quick Ratio: |
75.46% |
| Liquidity III / Current Ratio: |
219.78% |
| Debt / Equity Ratio: |
27.77% |
| Dynam. Debt / Equity Ratio: |
-1,488.48% |
Efficiency
| Employees: |
515 |
| Personal Expenses / Employee: |
- PLN |
| Revenues / Employee: |
420,516.50 PLN |
| Net Income / Employee: |
-54,609.71 PLN |
| Total Assets / Employee: |
1,105,452.43 PLN |
| * Fiscal Year End: |
31/12/2023 |
| Accounting Standard: |
IFRS |
